Search Results - "Zlatohlavek, L."

Statin-associated myopathy: from genetic predisposition to clinical management by Vrablik, M, Zlatohlavek, L, Stulc, T, Adamkova, V, Prusikova, M, Schwarzova, L, Hubacek, J A, Ceska, R

“…Statin-associated myopathy (SAM) represents a broad spectrum of disorders from insignificant myalgia to fatal rhabdomyolysis. Its frequency ranges from 1-5 %…”
Get full text

Statin-induced changes in mitochondrial respiration in blood platelets in rats and human with dyslipidemia by Vevera, J, Fišar, Z, Nekovářová, T, Vrablík, M, Zlatohlávek, L, Hroudová, J, Singh, N, Raboch, J, Valeš, K

“…3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used drugs for lowering blood lipid levels and preventing…”
Get full text

FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention by Zlatohlavek, L., Vrablik, M., Motykova, E., Ceska, R., Vasickova, L., Dlouha, D., Hubacek, J.A.

“…This study aimed to determine whether there is a relationship between common FTO (rs17817449) and MC4R (rs17782313) gene variants and body mass reduction or…”
Get full text

Biomarkers of cardiometabolic risk in obese/overweight children: effect of lifestyle intervention by Vrablík, M, Dobiášová, M, Zlatohlávek, L, Urbanová, Z, Češka, R

“…Obesity is a strong cardiometabolic (CM) risk factor in children. We tested potential CM risk in obese/overweight children and the effect of an intensive…”
Get full text

FH homozygote without cardiovascular disease at the age of 40 by Schwarzova, L, Hubacek, J.A, Fellnerova, A, Zlatohlavek, L, Prusíkova, M, Ceska, R, Vrablik, M

Get full text

Omega-3 fatty acids and cardiovascular disease risk: do we understand the relationship? by Vrablík, M, Prusíková, M, Šnejdrlová, M, Zlatohlávek, L

“…There is a large body of evidence documenting the effects of long-chain polyunsaturated fatty acids with the first double bond at the third position from…”
Get full text

Impact of variants within seven candidate genes on statin treatment efficacy by Vrablík, M, Hubáček, J A, Dlouhá, D, Lánská, V, Rynekrová, J, Zlatohlávek, L, Prusíková, M, Ceška, R, Adámková, V

“…Statins are the most commonly used drugs in patients with dyslipidemia. Among the patients, a significant inter-individual variability with supposed strong…”
Get full text

APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children by Zlatohlavek, L, Vrablik, M, Ceska, R, Adamkova, V, Urbanova, Z, Prusikova, M, Vasickova, L, Hubacek, J.A

Get full text

Lipoprotein(a) and its position among other risk factors of atherosclerosis by Zlatohlávek, L, Zídková, K, Vrablík, M, Haas, T, Prusíková, M, Svobodová, H, Ceska, R

“…Lipoprotein(a) [Lp(a)] comprises of an LDL particle and apolipoprotein(a) [apo(a)] and its elevated levels are considered a risk factor for atherosclerosis…”
Get full text

Dyslipidemia Control In Primary Care In The Czech Republic by Satny, M., Vrablik, M., Altschmiedova, T., Tumova, E., Vaclova, M., Snejdrlova, M., Zlatohlavek, L., Stulc, T., Horak, P., Grauova, B., Ceska, R.

Get full text

Familial dysbetalipoproteinemia – yes, or no? – Retrospective patient study of the center for preventive cardiology of the 3rd internal clinic first faculty of medicine and general university hospital by Satny, M., Grauova, B., Kasalova, E., Schwarzova, L., Snejdrlova, M., Stulc, T., Tumova, E., Tvrdikova, E., Vaclova, M., Zemankova, P., Zlatohlavek, L., Vrablik, M., Ceska, R.

Get full text

Clinical and demographic characteristics of patients with elevated Lp (a) in the Czech Republic by Becherová, J. Beňová, Zlatohlávek, L.

Get full text

General characteristics of pacients with homozygous form of familial hypercholesterolaemia in the Czech Republic by Tesarova, S., Blaha, V., Ceska, R., Dvorakova, J., Freiberger, T., Horak, P., Hyanek, J., Kyselak, O., Nussbaumerova, B., Soska, V., Urbanek, R., Vaclova, M., Vaverkova, H., Vrablik, M., Vyroubal, P., Zemek, S., Zlatohlavek, L.

Get full text

The effect change of pharmacotherapy of dyslipidemia from free to fixed combination, effect to adherence of the pharmacotherapy by Foglarová, T., Zlatohlávek, L., Mašatová, K.

Get full text

APOE polymorphism as a potential determinant of functional fitness in the elderly regardless of nutritional status by Snejdrlova, Michaela, Kalvach, Zdenek, Topinkova, Eva, Vrablik, Michal, Prochazkova, Renata, Kvasilova, Marie, Lanska, Vera, Zlatohlavek, Lukas, Prusikova, Martina, Ceska, Richard

“…Life expectancy is determined by a combination of genetic predisposition (~25%) and environmental influences (~75%). Nevertheless a stronger genetic influence…”
Get more information

Lifestyle modification induced weight loss and changes of cardiometabolic risk factors including lowering of inflammatory response in obese children by Motykova, Eva, Zlatohlavek, Lukáš, Prusikova, Martina, Lanska, Vera, Ceska, Richard, Vasickova, Ludmila, Vrablik, Michal

“…Obesity is associated with increased inflammation which represents a link to atherosclerosis and cardiovascular disease. Lipoprotein associated phospholipase…”
Get more information

Variability in apo(a) gene regulatory sequences, compound genotypes, and association with Lp(a) plasma levels by Zidkova, K, Zlatohlavek, L, Ceska, R

“…Lipoprotein(a) is an independent risk factor of atherosclerosis. We assigned frequencies of six polymorphic sites from apo(a) gene transcription control…”
Get full text

Hypertriglyceridemia: interaction between APOE and APOAV variants by Hubacek, Jaroslav A, Horínek, Ales, Skodova, Zdena, Adamkova, Vera, Ceska, Richard, Zlatohlavek, Lukas, Vráblík, Michal

Get full text

630 PHARMACOGENETICS OF STATIN TREATMENT EFFICACY: ANALYSIS OF GENETIC VARIATION AT EIGHT CANDIDATE GENE LOCI by Vrablik, M., Hubacek, J., Adamkova, V., Prusikova, M., Zlatohlavek, L., Lanska, V., Ceska, R.

Get full text

LIPID PROFILE AND LP(A) IN FIT AND HEALTHY ELDERLY by Zlatohlavek, L., Zidkova, K., Snejdrlova, M., Vrablik, M., Ceska, R.

Get full text